Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

31.89 -0.24 (-0.75%)
Streaming Delayed Price Updated: 10:20 AM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,825
Open 32.07
Bid (Size) 31.75 (1)
Ask (Size) 32.03 (1)
Prev. Close 32.13
Today's Range 31.65 - 32.21
52wk Range 24.10 - 62.53
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-38.1%
-38.1%
1 Month
-3.7%
-3.7%
3 Month
-7.9%
-7.9%
6 Month
-43.1%
-43.1%
1 Year
-31.9%
-31.9%

More News

Read More
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data
Via Benzinga
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
Via Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Via Benzinga
Exposures Product Safety
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?
Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market
What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?
The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 31.89
When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 06/05/25 10:20 AM ET
What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 1.72B
How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?
Crinetics Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.